Pacific Biomarkers CSO Elizabeth T. Leary Co-Authors Paper in March Issue of Clinical Chemistry
News Mar 09, 2011
Elizabeth T. Leary, PhD, Chief Scientific Officer at Pacific Biomarkers, Inc. (PBI), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, has co-authored a paper appearing in the March issue of Clinical Chemistry. The article explores the contribution of assay methodologies in the risk score classification of cardiovascular disease.
In the paper, Dr. Leary and her co-authors evaluated the accuracy of cardiovascular disease risk score classification by direct LDL cholesterol, calculated LDL cholesterol, and non-HDL cholesterol compared to classification by reference measurement procedures performed at the Centers for Disease Control and Prevention.
A total of 175 individuals were examined, including 138 with cardiovascular disease or conditions that may affect measurement of LDL cholesterol.
The study concluded that except for individuals with elevated triglycerides, 7 of 8 direct LDL cholesterol methods failed to show improved cardiovascular disease risk score classification over the corresponding calculated LDL cholesterol methods.
Non-HDL cholesterol showed overall the best concordance with the reference measurement procedures for cardiovascular disease risk score classification of both normal and hypertriglyceridemic individuals.
"Most clinical papers pretty much ignore assay differences and their contribution in the interpretation of study findings," said Dr. Leary. "We have presented evidence that not all assays for cardiovascular risk are equally accurate, a conclusion that may help select the appropriate assay for each study and refine methodologies that target those patients at risk for cardiovascular disease."
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
£70M Meant for Cancer Drug Development is Reassigned to Prepare for BrexitNews
At the end of last year, the Health Committee held a meeting to discuss Brexit, more specifically the impact this will have on the discovery, development and regulation of medicines, medical devices and biopharmaceuticals.READ MORE